Startups

Head of Medical Affairs

Remix Therapeutics · Watertown, MA · On-site

← All jobs
About Remix Therapeutics

Backed by Atlas Venture.

About the role

Remix is seeking a Head of Medical Affairs to provide medical affairs leadership for REM-422 and contribute to the development of future programs across the portfolio. REM-422 is an innovative investigational therapy targeting RNA splicing machinery, with adenoid cystic carcinoma (ACC), a rare salivary gland cancer, as its first clinical indication.

What they're looking for

  • Advanced life science degree required. MD or equivalent medical degree preferred, PhD or PharmD considered
  • 10+ years in medical affairs and prior leadership of the function
  • Oncology experience is required. Solid tumors strongly preferred, head and neck or salivary gland is a distinct advantage
  • Built a Medical Affairs function from an early state rather than only running an established one
  • Launch experience preferred, ideally with a first in class or first in disease product where the treatment pathway had to be established
  • Existing relationships across oncology academic institutions
More about this role

Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.

Remix is seeking a Head of Medical Affairs to provide medical affairs leadership for REM-422 and contribute to the development of future programs across the portfolio. REM-422 is an innovative investigational therapy targeting RNA splicing machinery, with adenoid cystic carcinoma (ACC), a rare salivary gland cancer, as its first clinical indication. With no approved therapy for ACC, this is an opportunity to help shape the medical and treatment landscape for patients with a rare cancer while playing a key role in advancing a novel therapeutic approach.

Reporting directly...

Read the full posting on Remix Therapeutics's site ↗

Medical Affairs

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.